Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Apexigen, Inc. (NASDAQ: APGN), a clinical-stage biopharmaceutical company specializing in antibody-based cancer therapies, announced participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company will deliver a pre-recorded presentation on September 12, accessible at 7:00 a.m. ET. An archived version will be available on Apexigen's website. Apexigen focuses on innovative immuno-oncology agents, leveraging its APXiMAB™ platform to discover new therapeutic antibodies, with several candidates in clinical development.

SAN CARLOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Company’s Management will participate virtually in the H.C. Wainwright 24^th Annual Global Investment Conference, to be held virtually and in New York, NY from September 12-14, 2022.

H.C. Wainwright 24^th Annual Global Investment Conference
Format: Pre-recorded presentation and one-on-one investor meetings
Date: Monday, September 12, 2022
Time: Presentation available at 7:00 a.m. ET
Webcast: Click Here

An archived webcast of the presentation will be accessible in the Events & Presentations section of the company’s website at https://www.apexigen.com.

About Apexigen, Inc.
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Multiple product candidates have been discovered using the APXiMAB platform, one of which is commercially available and the others are in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.

Investor Contact:
Bruce Mackle
LifeSci Advisors
+1-646-889-1200
bmackle@lifesciadvisors.com

Apexigen Contact:
William Duke
Chief Financial Officer
Apexigen, Inc.
+1-650-931-6236
ir@apexigen.com

FAQ

When is Apexigen participating in the H.C. Wainwright 24th Annual Global Investment Conference?

Apexigen will participate in the conference from September 12-14, 2022.

What time will Apexigen's presentation be available during the conference?

Apexigen's pre-recorded presentation will be available on September 12, 2022, at 7:00 a.m. ET.

Where can I find the archived webcast of Apexigen's presentation?

The archived webcast will be accessible on Apexigen's website in the Events & Presentations section.

What is the main focus of Apexigen's research?

Apexigen focuses on developing antibody-based therapies for cancer, particularly through immuno-oncology.

What platform does Apexigen use to discover therapeutic antibodies?

Apexigen utilizes its proprietary APXiMAB™ discovery platform to develop new antibody therapeutics.